Hepatic Encephalopathy Market, by Drug Class (Antibiotics, Laxatives, L-ornithine L-aspartate, and others), by Route of administration (Oral, Intravenous, Rectal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023

Code : CMI2596

Pages :210

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Hepatic Encephalopathy Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020. The market for managing liver disease continues to have a positive impact overall from COVID-19. The rise in COVID-19 prevalence has fueled the desire for precise diagnosis and treatment tools in a number of nations. Solutions for managing liver diseases have proven to be highly beneficial in this regard since they enable healthcare providers to easily combine SGLT1 and SGLT2, patient management, and care management solutions with solutions for healthcare payers, such as claim management and payment management systems. Additionally, lockdowns and restrictions brought on by the disease's quick global spread have raised the requirement for electronic data transfer and claim administration.

In particular, the pandemic – now at its two-year mark – has played a pivotal role in changing the health landscape by hindering hepatic encephalopathy for many patients, raising the specter of more severe illness for many with underlying health conditions. Such factors are contributing to a rise in mortality or some of the leading causes of death in the U.S., such as hepatitis A, B and Hepatitis C and liver failure.

High cost associated the treatment of hepatic encephalopathy

High cost of the treatment of overt hepatic encephalopathy (OHE) is one of the factors that are restraining the growth of the market in the forecast period. For instance, according to the National Center for Biotechnology Information, in 2022, hepatic encephalopathy is the second most common reason for hospitalization in patients suffering from liver cirrhosis, in the U.S., after ascites. According to the same source, the national expenditures for the U.S., related to hospitalizations for hepatic encephalopathy have been estimated to range from around US$ 1 billion per year to above US$ 7 billion per year.